Indian regulator approves Favipiravir for the treatment of mild to moderate COVID-19 in India

Glenmark Pharmaceuticals has just received the manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir (FabiFlu®) for the treatment of mild to moderate COVID-19 patients in India. This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.409.1 as compared to the previous close of Rs. 405.35. The total number of shares traded during the day was 170709 in over 3247 trades.

The stock hit an intraday high of Rs. 416.75 and intraday low of 407.7. The net turnover during the day was Rs. 70392056.

Source : Equity Bulls

Keywords